About us

What we do


We offer a specialized service based on a unique human whole-blood loop assay, for detection of acute immune-related side effects of biopharmaceuticals (cytokine release), which provides a better understanding of first-in-man reactions prior to clinical trial entry. The assay platform can also be used to perform mode-of-action studies.

Read more


We are developing a new generation therapeutic peptide-based immuno-oncology vaccine powered by proprietary and patent-protected advanced TET technology that will enhance both peptide uptake and cellular immune activation. Our strategy is based on the delivery of our vaccine in an antigen-antibody immune complex formula. The primary focus is early stage, high-risk prostate cancer but the platform can be used for developing vaccines for other indications.

Read more

Sign up!

Meet us at Nordic Life Science Days in Malmö September 12-14. During the conference, Justyna Leja-Jarblad, Laboratory Manager will give a pitch about our Immuno-Oncology project, at the Start Up Challenge on September 12 at 18:30. We are open to partnering meetings throughout the conference. Come and talk to us about our Immuno-Service, Immuno-Oncology, potential collaboration, or anything that interests you!

Immuneed has secured SEK 9M in an oversubscribed financing round. The funding will support the pre-clinical work of our Immuno-Oncology cancer vaccine and be used to increase marketing of the companys analysis service. The new funding secures financing of our pre-clinical program for the cancer vaccine and further engagement for contract manufacturing.

Watch this space

Because we're up to something good...

Quick Links

Dag Hammarskjölds väg 13a | 752 37 Uppsala, Sweden | info@immuneed.com